Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

Topline results from phase II AURORA trial of avacopan reported

Oct. 30, 2020

MediWound completes enrollment in phase II pediatric study of NexoBrid

Oct. 30, 2020

First patient dosed in phase II study of BBP-589

Oct. 29, 2020

Phase II study of SHR-0302 in atopic dermatitis meets primary and secondary endpoints

Oct. 27, 2020

First patient dosed in phase IIa study of ATI-1777

Oct. 21, 2020

Genfleet Therapeutics patents RIP-1 inhibitors

Oct. 16, 2020

AnaptysBio reports topline data from phase II GALLOP study of imsidolimab in GPP

Oct. 14, 2020

Hisamitsu Pharmaceutical initiates phase III study of HP-5070 in Japan

Oct. 9, 2020

IDMC recommends piclidenoson psoriasis study continue, rheumatoid arthritis trial end

Oct. 8, 2020

Galapagos begins patient dosing with GLPG-3970 in psoriasis

Oct. 1, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...